Skip to main content
Premium Trial:

Request an Annual Quote

UH Case Medical Center, Arup Labs Reach Marketing Deal on Sequencing-based HIV Test

NEW YORK (GenomeWeb) – University Hospital Case Medical Center today said it has reached a deal with Arup Laboratories to offer a sequencing-based HIV diagnostic test.

The test, called Deepgen-HIV, was developed by Miguel Quinones-Mateu, scientific director at the UH lab and an assistant professor in the department of pathology at Case Western Reserve University School of Medicine. Under the terms of the deal, Arup will include the test in its offerings and market it nationally. The UH Translational Laboratory in Cleveland will perform the test.

Using deep sequencing, Deepgen-HIV determines drug resistance and the ability of HIV to infect different cells, allowing clinicians and researchers to monitor the effectiveness of an HIV treatment. The assay detects minority variants at frequencies "unimaginable with current HIV genotypic tests based on standard (Sanger) sequencing," UH said in a statement.

While the clinical relevance of the minority members of the viral population is still under debate, "it is reasonable to assume that the earlier these mutant viruses are detected, the sooner the proper strategy can be defined to control their growth," Quinones-Mateu said. The Arup agreement, he added, will accelerate the use of Deepgen-HIV, "which will allows us to enhance the care and treatment of HIV-infected individuals across the country."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more